figs4.

MB and MPA inhibit SARS-CoV-2 infection of bronchial HAEEC. Bronchial HAEEC grown at air-liquid interface were inoculated apically with 1,000 FFU of SARS-CoV2 (day 0), and subjected to drug treatment in the basolateral medium. Drugs were applied in a pre-infection regimen, starting at 2h prior to SARS-CoV2 inoculation (A, C) or in a post-infection regimen starting at 1d post inoculation (B, D). MB (5 and 0.5 μM) and MPA (10 and 1 μM) were administrated daily until day 8. DMSO was used as a negative control. SARS-CoV-2 released to the apical side was collected daily by apical washing and quantified by virus TCID₅₀ titration. Data represent the mean±SEM of two independent replicates. Not determined (nd) indicates virus titers below 2.4 log10 TCID₅₀/ml in the two replicates, and (1/2) indicates virus titers below 2.4 log10 TCID₅₀/ml in one replicate.